Characterization of Immunosuppressive Signing of Cervical Cancer
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 50
- 试验地点
- 2
- 主要终点
- Lack of tumor emboli histological analysis
研究概览
简要总结
Infection with Human Papillomavirus high-risk Human (HR-HPV) is the main factor of risk of cancer of the cervix. Recent studies show that cancers linked to infection with HR-HPV are associated with immunosuppression and lack of T cell response Such mechanisms would promote progression to cancer and progression of it . Various factors such as an increase of regulatory T cells, the presence of myeloid cells and suppressor of defects in the signaling pathway Toll Like Receptor (TLR) may have a key role in these immunosuppression mechanisms. At this stage of knowledge, a better characterization of local and systemic immunosuppressive signing of cervical cancer is needed. The results should have a significant medical impact for the identification of new prognostic markers and new therapeutic targets for the treatment of patients with cervical cancer.
The aim of this research project is to define the signing of immunosuppressive cancer cervix and analyze the different mechanisms involved in this immunosuppression.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •The women presenting for initial therapeutic management of cervical cancer
- •Elderly patients over 18 years
- •Patients beneficiary of a social security scheme
- •Pregnant women can not participate in this study
- •Women known to be HIV positive will not participate in this study
排除标准
- •Patients with a recurrence of a treaty cervical cancer
- •Patients with a history of pelvic radiotherapy
- •Patients unable to receive informed about the progress and objectives of the study
- •Patients not receiving a social security scheme
- •Patients who have not signed informed consent
- •Immunocompromised patients and pregnant women
结局指标
主要结局
Lack of tumor emboli histological analysis
时间窗: 60 months
Patients with good prognosis of cervical cancer
次要结局
未报告次要终点